Limited weight impact after switching from boosted protease ihibitors to dolutegravir in persons with human immunodeficiency virus with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial

NEAT 022 Study Grp

    Research output: Contribution to journalA1: Web of Science-articlepeer-review

    Fingerprint

    Dive into the research topics of 'Limited weight impact after switching from boosted protease ihibitors to dolutegravir in persons with human immunodeficiency virus with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial'. Together they form a unique fingerprint.

    Medicine & Life Sciences